Navigation Links
Boehringer Ingelheim's Investigational Therapy Nintedanib Receives FDA Breakthrough Therapy Designation
Date:7/16/2014

RIDGEFIELD, Conn., July 16, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food & Drug Administration (FDA) has granted Breakthrough Therapy designation to nintedanib, an investigational therapy currently under FDA review for the treatment of people with idiopathic pulmonary fibrosis (IPF). The efficacy and safety of nintedanib in the treatment of IPF has not been established.

"Boehringer Ingelheim is proud that the FDA has granted Breakthrough Therapy designation for nintedanib, which will help expedite its development and review as a potential treatment option for patients with IPF," said Sabine Luik, M.D., senior vice president, Medicine & Regulatory Affairs at Boehringer Ingelheim Pharmaceuticals, Inc. "We are committed to working with the FDA during the NDA review of nintedanib for people living with this serious and life-threatening lung disease, for which there are currently no FDA-approved treatment options."

The Breakthrough Therapy designation process was established by the FDA in 2012 and is intended to expedite the development and review of drugs for serious or life-threatening conditions, and preliminary clinical evidence indicates that the therapy may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints.

IPF is a serious and life-threatening lung disease that causes permanent scarring of the lungs, difficulty breathing and decreases the amount of oxygen the lungs can supply to the body. IPF affects as many as 132,000 Americans. There are currently no FDA-approved treatments.

Results from two global Phase 3 studies (INPULSIS™-1 and INPULSIS™-2) evaluating the efficacy and safety of nintedanib in the treatment of IPF were presented at the American Thoracic Society (ATS) International Conference and published in the New England Journal of Medicine in May 2014.

'/>"/>
SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Circuit Therapeutics and Boehringer Ingelheim announce signature of a research partnership agreement to discover new approaches to treating psychiatric disorders
2. Apollo Medical Holdings and Boehringer Ingelheim to Collaborate On Care of ApolloMed Accountable Care Organization (ACO) Patients with COPD
3. Largest Global Survey Investigating Early Type 2 Diabetes Conversations Launched by Boehringer Ingelheim and Eli Lilly and Company in Partnership with the International Diabetes Federation
4. Boehringer Ingelheims Jeff Huth Elected as National Pharmaceutical Councils Chairman of the Board
5. Boehringer Ingelheims interferon-free hepatitis C treatment portfolio strengthened by promising interim Phase 2a data
6. Pivotal Phase 3 Data from Boehringer Ingelheim Hepatitis C Portfolio to be Presented at 64th Annual AASLD Meeting
7. Boehringer Ingelheim Pharmaceuticals, Inc. colabora con Univision Communications Inc. para lanzar una campaña integrada en español
8. Boehringer Ingelheim Pharmaceuticals, Inc. Collaborates With Univision Communications Inc. To Launch An Integrated Campaign In Spanish
9. Boehringer Ingelheims investigational volasertib receives FDA Breakthrough Therapy designation
10. Boehringer Ingelheim Expands Investigation of Interferon-free Hepatitis C Treatment Regimens to Reach More Patient Types through Presidio Pharmaceuticals Clinical Collaboration
11. Boehringer Ingelheim Pharmaceuticals, Inc. Statement on RE-ALIGN Data
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)...  ResMed Inc. (NYSE: RMD ) today announced ... ended June 30, 2014.  Revenue for the quarter was $415.2 ... (a 1 percent decrease on a constant currency basis). Net ... to the quarter ended June 30, 2013. Diluted earnings per ... percent compared to the quarter ended June 30, 2013.  ...
(Date:7/31/2014)... Calif., July 31, 2014 Pharmacyclics, Inc. (the "Company") ... recent developments for the quarter ended June 30, 2014. ... June 30, 2014 Revenue Total revenue for the quarter ... million for the quarter ended June 30, 2013 primarily due ... million. Total revenue for the six months ...
(Date:7/31/2014)... MOUNTAIN VIEW, Calif. , July 31, 2014 ... ) today provided an update on its pipeline ... of 2014, Alexza expects to initiate a Phase ... which is being developed for the management of ... identified two new Staccato -based product candidates ...
Breaking Medicine Technology:RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 3RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 4RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 5RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 6RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 7RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 8RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 9RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 10RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 11RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 12RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 13Pharmacyclics Reports Second Quarter 2014 Results 2Pharmacyclics Reports Second Quarter 2014 Results 3Pharmacyclics Reports Second Quarter 2014 Results 4Pharmacyclics Reports Second Quarter 2014 Results 5Pharmacyclics Reports Second Quarter 2014 Results 6Pharmacyclics Reports Second Quarter 2014 Results 7Pharmacyclics Reports Second Quarter 2014 Results 8Pharmacyclics Reports Second Quarter 2014 Results 9Pharmacyclics Reports Second Quarter 2014 Results 10Pharmacyclics Reports Second Quarter 2014 Results 11Pharmacyclics Reports Second Quarter 2014 Results 12Pharmacyclics Reports Second Quarter 2014 Results 13Pharmacyclics Reports Second Quarter 2014 Results 14Pharmacyclics Reports Second Quarter 2014 Results 15Pharmacyclics Reports Second Quarter 2014 Results 16Pharmacyclics Reports Second Quarter 2014 Results 17Pharmacyclics Reports Second Quarter 2014 Results 18Pharmacyclics Reports Second Quarter 2014 Results 19Pharmacyclics Reports Second Quarter 2014 Results 20Pharmacyclics Reports Second Quarter 2014 Results 21Pharmacyclics Reports Second Quarter 2014 Results 22Pharmacyclics Reports Second Quarter 2014 Results 23Pharmacyclics Reports Second Quarter 2014 Results 24
... Contaminated with Diethylene Glycol,(DEG) Remains a Potential ... Md., May 4, 2007-The U.S. Food and ... repackers, and health professionals who compound,medications to ... a,sweetener commonly used worldwide in liquid over-the-counter ...
... ROCKVILLE, Md., April 25, 2007-The U.S. Food ... a Consent Decree of,Permanent Injunction against PharmaFab ... officials, Mark Tengler, PharmaFab's president,and Russ McMahen, ... the illegal manufacture and distribution of prescription ...
Cached Medicine Technology:FDA Advises Manufacturers to Test Glycerin for Possible,Contamination 2Major Manufacturer of Unapproved and Adulterated Drugs 2Major Manufacturer of Unapproved and Adulterated Drugs 3
(Date:8/1/2014)... The Judicial Panel on Multidistrict Litigation ... therapy caused strokes, heart attacks, and other injuries in ... F. Kennelly as the transferee judge and ordered what ... federal court. , As one of his first organizing ... of attorneys who will move the litigation forward on ...
(Date:8/1/2014)... central role in regulating appetite and whole-body metabolism. A ... control of food intake and body weight, but the ... unclear. A new study in the ... in a type of neuron known as pro-opiomelanocortin (POMC) ... diet. Sabrina Diano and colleagues at Yale University ...
(Date:8/1/2014)... 2014 Stryker hip lawsuits ( ... 2012 Rejuvenate and ABG II Modular-Neck Hip Stem ... Bergen County Superior Court, Bernstein Liebhard LLP reports. ... Court has issued a Final Amended Stipulated ... hard copy and electronic materials produced by any ...
(Date:8/1/2014)... CLEVELAND, Ohio In a first-of-its-kind study, researchers at ... found that lap infants may be at greater risk ... analyzed pediatric medical emergencies on flights worldwide between January ... deaths occurred in children under the age of 2. ... MedAire to characterize the rare event of an in-flight ...
(Date:8/1/2014)... Vegas, NV (PRWEB) August 01, 2014 ... and opportunities for independent community pharmacies. At ThoughtSpot ... pharmacists are equipped with practices and resources to ... Session, AmerisourceBergen leaders focused on critical issues to ... learn, optimize and grow. , ThoughtSpot show ...
Breaking Medicine News(10 mins):Health News:Judge Kennelly Appoints Attorney Michelle Kranz to the Plaintiffs’ Executive Committee in the Testosterone Replacement Therapy MDL 2Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 2Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 3Health News:New research characterizes in-flight pediatric deaths 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 3Health News:ThoughtSpot 2014 Inspires as General Session Concludes 4Health News:ThoughtSpot 2014 Inspires as General Session Concludes 5
... "Thomson Reuters Citation Laureates" Recognized for Their,Contributions to ... Oct. 1 The Scientific business,of Thomson Reuters ... researchers likely to be in contention for Nobel ... winners to be announced in October., Each ...
... of serious public health issue through first ... Sudden cardiac arrest (SCA) claims,more lives each year ... a new Heart Rhythm Society survey, four out of ... health issue that causes,more than 250,000 deaths each year. ...
... developed a method of using nanoparticles to deliver treatments ... team led by Richard Borgens of the School of ... of Biomedical Engineering coated silica nanoparticles with a polymer ... That research is being published in the October edition ...
... Recession Fears - List Reports Aggregate Revenue of $185 Billion; Nuclear ... 100 Health Companies and No. 1161 on the Inc. 5000 With ... ... (PRWEB) October 1, 2008 -- Inc. today ranked www.mobilenuclear.com [Nuclear Medicine ...
... Ticker Symbol: CUR, QUEBEC CITY, Oct. 1 ... company commercializing high-value cancer diagnostic,tests and delivering laboratory ... CEO of the Company, will be presenting a ... Focus Conference on,Monday, October 6, 2008, at 1:30 ...
... with No Monthly ... Premium, ... serving seniors and others with Medicare,announced today that its new Medicare Advantage ... with no monthly plan premiums and no deductibles., "Access to affordable, ...
Cached Medicine News:Health News:The Scientific Business of Thomson Reuters Predicts Nobel Laureates 2Health News:The Scientific Business of Thomson Reuters Predicts Nobel Laureates 3Health News:The Scientific Business of Thomson Reuters Predicts Nobel Laureates 4Health News:The Scientific Business of Thomson Reuters Predicts Nobel Laureates 5Health News:New Research: Americans Underestimate Dangers of Sudden Cardiac Arrest 2Health News:New Research: Americans Underestimate Dangers of Sudden Cardiac Arrest 3Health News:New Research: Americans Underestimate Dangers of Sudden Cardiac Arrest 4Health News:Researchers use nanoparticles to deliver treatment for brain, spinal cord injuries 2Health News:America's 5000 Fastest-Growing Private Companies Revealed 2Health News:DiagnoCure to present at the JMP Securities Healthcare Focus Conference on October 6, 2008 2Health News:SCAN Health Plan Arizona Announces Its 2009 MAPD Benefits for Maricopa County 2
... Slimline single-use pH catheters are ... cross-contamination and allow greater patient comfort ... ,Medtronic pH measurement systems have been ... that allow an accurate room-temperature calibration. ...
FLEXILOG spare part....
FLEXILOG spare part....
Complete calibration kits are available for both pH and manometry systems....
Medicine Products: